Table 3.
Prognostic factors of recurrence-free survival in propensity score-matched pairs
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age | 0.993 (0.976~1.010) | 0.421 | ||
| Gender (male) | 1.587 (0.909~2.769) | 0.104 | ||
| TBIL | 0.995 (0.963~1.028) | 0.758 | ||
| ALT | 1.003 (0.998~1.008) | 0.199 | ||
| AST | 1.006 (0.999~1.013) | 0.111 | ||
| ALB | 0.963 (0.918~1.009) | 0.116 | ||
| PT | 0.894 (0.748~1.068) | 0.215 | ||
| CREA | 1.007 (0.994~1.020) | 0.300 | ||
| AFP (> 400 ng/mL) | 1.163 (0.760~1.780) | 0.485 | ||
| Tumor size (3~5 cm) | 1.077 (0.725~1.601) | 0.714 | ||
| Tumor number (2~3) | 2.807 (1.391~5.664) | 0.004 | 2.561 (1.658~3.955) | < 0.001 |
| Transfusion (+) | 0.877 (0.350~2.194) | 0.779 | ||
| Cirrhosis (+) | 1.744 (0.774~3.931) | 0.180 | ||
| MVI (+) | 2.837 (1.694~4.750) | < 0.001 | 1.970 (1.407~2.757) | < 0.001 |
| Poor differentiation (+) | 3.778 (2.483~5.750) | < 0.001 | 1.399 (1.024~1.911) | 0.035 |
| PLT (< 100 × 109/L) | 1.534 (1.031~2.282) | 0.035 | 1.388 (1.028~1.874) | 0.033 |
HR hazard ratio, CI confidence interval, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, PT prothrombin time, CREA creatinine, AFP alpha-fetoprotein, MVI microvascular invasion, PLT platelet counts